Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT

NCT07448727 · clinicaltrials.gov ↗
RECRUITING
Status
25
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

University of Rome Tor Vergata